BofA analyst Jason Gerberry lowered the firm’s price target on Lenz Therapeutics (LENZ) to $29 from $35 and keeps a Buy rating on the shares. After having updated its model to reflect Q1 script trends, the firm lowered its FY26 VIZZ revenue forecast to $25M from $49M and FY27 to $80M from $111M, the analyst tells investors following the company’s Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ: